Kodiak Sciences Q2 net loss $90.6M; BEACON Phase 3 RVO study meets endpoint

Kodiak Sciences Inc.

2022-Q2 EPS reported -$3.57

Net loss of $90.6M ($1.74/share) vs $55.9M ($1.08/share) in Q2 2021 driven by higher R&D and stock-based comp.
Cash and equivalents $597.9M at quarter-end, down from prior quarter but sufficient for operations.
BEACON study in RVO met primary endpoint: tarcocimab every 8 weeks non-inferior to aflibercept monthly.
Phase 3 DME studies GLEAM/GLIMMER and wet AMD study DAYLIGHT fully enrolled; topline data expected mid-2023.
Plans to file single BLA for tarcocimab across all indications if Phase 3 data are positive.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.